Effect of the route and mode of agonist delivery on functional behaviour of the airways.

Respir Physiol

Meakins-Christie Laboratories, Royal Victoria Hospital, McGill University, Quebec, Canada.

Published: October 1996

There is evidence that the mode of smooth muscle agonist delivery affects the changes induced in lung mechanical properties. The object of this investigation was to study modifications in airway behaviour associated with different modes of agonist delivery. Tracheal (Ptr) and alveolar pressure (PA) and flow (V) were measured in open-chested, mechanically ventilated (f = 1 Hz, VT = 10 ml/kg, PEEP = 4 cm H2O) rats under baseline conditions and during administration of repeated intravenous (i.v.) bolus, i.v. continuous infusion and aerosols of methacholine (MCh). We calculated lung elastance (EL) and lung resistance (RL) by fitting the equation of motion to changes in Ptr and V. We assessed the patency of the airway pathways and local dynamic hyperinflation by comparing Ptr vs PA. Comparison of the three different modes of MCh delivery showed a difference in the functional behaviour of the airways. In the aerosol group a larger incidence of highly constricted airways was observed. Conversely, the i.v. groups showed a larger incidence of regional dynamic hyperinflation. In the bolus group a different time course in the development of dynamic hyperinflation was observed for different pathways within the same animal. For consecutive challenges a given pathway tended to behave in the same manner, suggesting the response was characteristic for that pathway. In this study we have shown that, even though different airway pathways show different intrinsic reactivity, the mode of agonist delivery plays a role in determining functional airway behaviour.

Download full-text PDF

Source
http://dx.doi.org/10.1016/0034-5687(96)00059-xDOI Listing

Publication Analysis

Top Keywords

agonist delivery
16
dynamic hyperinflation
12
mode agonist
8
functional behaviour
8
behaviour airways
8
airway behaviour
8
airway pathways
8
larger incidence
8
delivery
5
route mode
4

Similar Publications

SERCA2 dysfunction accelerates angiotensin II-induced aortic aneurysm and atherosclerosis by induction of oxidative stress in aortic smooth muscle cells.

J Mol Cell Cardiol

January 2025

School of Pharmaceutical Sciences, Chongqing University, Chongqing 401331, China; State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Harbin Medical University, China; Chongqing Key Laboratory of New Drug Delivery System, Chongqing 400038, China. Electronic address:

Background And Aim: Our previous research indicates that sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (SERCA2) dysfunction facilitates the phenotypic transformation of aortic smooth muscle cells (ASMCs) and intensifies aortic aneurysm through the regulation of calcium-dependent pathways and endoplasmic reticulum stress. Our hypothesis is that additional mechanisms are involved in aortic aneurysm and atherosclerosis induced by SERCA2 dysfunction from the perspective of ASMC phenotypic transformation.

Methods & Results: In SERCA2 dysfunctional mice and their control littermates, ASMCs were isolated to analyze protein expression and cell functions, and angiotensin II was infused into these mice that were backcrossed into LDL receptor deficient background to induce aortic aneurysm and atherosclerosis.

View Article and Find Full Text PDF

Background And Objective: A gonadotropin-releasing hormone (GnRH) agonist such as leuprolide is widely used to achieve sustained suppression of testosterone levels, which play a critical role in the treatment of prostate cancer. Recent advances in drug delivery systems have led to the development of long-acting depot formulations, such as the 6-month intramuscular (IM) leuprolide formulation, which aim to simplify dosing and improve convenience for both patients and healthcare providers. Exploring extended dosing intervals for such formulations represents a promising approach to further optimize treatment regimens, potentially balancing efficacy with patient-centered care.

View Article and Find Full Text PDF

PD-L1/PD-1 checkpoint inhibitors (CPIs) are mainstream agents for cancer immunotherapy, but the prognosis is unsatisfactory in solid tumor patients lacking preexisting T-cell reactivity. Adjunct therapy strategies including the intratumoral administration of immunostimulants aim to address this limitation. CpG oligodeoxynucleotides (ODNs), TLR9 agonists that can potentiate adaptive immunity, have been widely investigated to tackle PD-L1/PD-1 resistance, but clinical success has been hindered by inconsistent efficacy and immune-related toxicities caused by systemic exposure.

View Article and Find Full Text PDF

Cota is a lipidated dual GLP-1 and Glucagon receptor agonist that was investigated for the treatment of various metabolic diseases, it is designed for once daily subcutaneous administration. Invasive daily injections often result in poor patient compliance with chronic disease, and here, we demonstrate an innovative strategy of encapsulating reversible cota self-assembled fibers within an in-situ forming depot of low molecular weight poly(lactic-co-glycolic) acid (LWPLGA) for sustained delivery GLP-1 and Glucagon receptor agonist with controlled burst release. This could be a suitable alternative to other sustained delivery strategies for fibrillating peptides.

View Article and Find Full Text PDF

Background: Opioid Agonist Treatment (OAT) is the most effective intervention for opioid use disorder (OUD), but retention has decreased due to increasingly potent drugs like fentanyl. This cohort can be used retrospectively to observe trends in service utilization, healthcare integration, healthcare costs and patient outcomes. It also facilitates the design of observational studies to mimic a prospective design.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!